ERTS Wealth Advisors LLC Takes Position in Bristol-Myers Squibb Co (BMY)

ERTS Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the fourth quarter, HoldingsChannel reports. The firm acquired 5,552 shares of the biopharmaceutical company’s stock, valued at approximately $289,000.

Several other institutional investors have also bought and sold shares of BMY. Bank of New York Mellon Corp increased its holdings in shares of Bristol-Myers Squibb by 1.6% in the third quarter. Bank of New York Mellon Corp now owns 17,123,173 shares of the biopharmaceutical company’s stock valued at $1,063,006,000 after purchasing an additional 277,927 shares during the period. Martingale Asset Management L P grew its holdings in Bristol-Myers Squibb by 12.7% during the third quarter. Martingale Asset Management L P now owns 556,353 shares of the biopharmaceutical company’s stock worth $34,540,000 after acquiring an additional 62,836 shares during the period. Rafferty Asset Management LLC acquired a new position in Bristol-Myers Squibb during the third quarter worth $207,000. Standard Life Aberdeen plc grew its holdings in Bristol-Myers Squibb by 9.9% during the third quarter. Standard Life Aberdeen plc now owns 533,866 shares of the biopharmaceutical company’s stock worth $33,143,000 after acquiring an additional 48,146 shares during the period. Finally, CLS Investments LLC grew its holdings in Bristol-Myers Squibb by 194.3% during the third quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 1,700 shares during the period. Institutional investors own 74.27% of the company’s stock.

BMY opened at $47.09 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.50 and a debt-to-equity ratio of 0.40. The firm has a market cap of $77.89 billion, a price-to-earnings ratio of 11.83, a PEG ratio of 2.43 and a beta of 0.80. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. Bristol-Myers Squibb’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 earnings per share. On average, equities analysts anticipate that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.41 per share. The ex-dividend date is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a yield of 3.48%. Bristol-Myers Squibb’s payout ratio is 41.21%.

BMY has been the topic of a number of recent analyst reports. Morgan Stanley set a $54.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, December 20th. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. BMO Capital Markets reaffirmed a “buy” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, February 19th. Societe Generale raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a report on Tuesday, January 15th. Finally, Bank of America set a $53.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Friday, January 25th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $59.13.

TRADEMARK VIOLATION WARNING: “ERTS Wealth Advisors LLC Takes Position in Bristol-Myers Squibb Co (BMY)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://sportsperspectives.com/2019/04/02/erts-wealth-advisors-llc-takes-position-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Candlestick

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.